y12F Antibody

What is the Y12 antibody and what are its primary research applications?

Y12 antibodies represent a family of monoclonal antibodies with specific research applications across immunology and molecular biology. The Anti-Sm [Y12] antibody is a mouse-derived monoclonal antibody (IgG3 kappa isotype) that recognizes Sm proteins found in small ribonucleoprotein particles (snRNPs) . These snRNPs play crucial roles in pre-mRNA splicing mechanisms. Y12 antibodies are particularly valuable in studying autoimmune conditions like Systemic Lupus Erythematosus (SLE), where anti-Sm antibodies appear in 20-30% of patients .

In another context, Anti-Bevacizumab Antibody (AY12) is a mouse monoclonal antibody produced from hybridoma created by fusing SP2/0 myeloma and mouse B-lymphocytes . This antibody specifically recognizes bevacizumab, making it useful for pharmaceutical research and drug development studies involving this therapeutic antibody .

What are the optimal storage conditions for Y12 antibodies?

For maintaining Y12 antibody stability and activity, proper storage is critical. The Anti-Bevacizumab Antibody (AY12), for example, should be stored in lyophilized state at -20°C or lower for long-term preservation . Researchers should avoid repeated freeze-thaw cycles as these can significantly degrade antibody function .

When reconstituting lyophilized Y12 antibodies, follow the specific Certificate of Analysis (CoA) instructions provided with your product. Typically, these antibodies are lyophilized from 0.22 μm filtered solutions in buffers containing stabilizing agents such as Tris with Glycine, Arginine, NaCl (pH 7.5), and trehalose as a protectant .

How do Y12 antibodies compare to other antibodies targeting similar epitopes?

Y12 antibodies offer distinct advantages in their respective research applications. The Anti-Sm [Y12] antibody has been specifically validated for quantitative radioimmunoassays in SLE patients, providing reliable detection of Sm autoantigen complexes containing RNA and protein . Its high specificity for Sm proteins makes it particularly valuable for studying the role of snRNPs in disease mechanisms.

For Anti-Bevacizumab Antibody (AY12), its specificity for bevacizumab enables precise detection without cross-reactivity issues, allowing for accurate measurement in complex biological samples. This specificity is essential for applications like anti-drug antibody (ADA) assay development, where distinguishing the therapeutic antibody from other proteins is critical .

What methodological considerations should be taken when using Y12 antibodies in ELISA assays?

When incorporating Y12 antibodies into ELISA protocols, several methodological factors require careful attention. For Anti-Bevacizumab Antibody (AY12), the recommended usage concentration for ELISA applications ranges from 0.1-100 ng/mL . This broad range allows researchers to optimize antibody concentration based on their specific experimental conditions and detection sensitivity requirements.

For bridging ELISA formats used in Anti-Drug Antibody (ADA) assay development, a systematically optimized approach is necessary. As demonstrated with Anti-Bevacizumab Antibody (AY12), immobilizing bevacizumab at 5 μg/mL, then adding increasing concentrations of the antibody (in 10% human serum), followed by biotinylated bevacizumab at 5 μg/mL provides a sensitive detection system with sensitivity reaching 62 ng/mL .

How can researchers optimize neutralization assays using Y12 antibodies?

Neutralization assays with Y12 antibodies require careful optimization to achieve reliable results. For the Anti-Bevacizumab Antibody (AY12), functional ELISA assays demonstrate its neutralizing ability with high efficiency. When immobilizing bevacizumab at 2 μg/mL (100 μL/well), pre-mixed Anti-Bevacizumab Antibody (AY12) and Biotinylated Human VEGF165 can achieve an inhibition rate of 96% . This high neutralization capacity indicates the antibody's strong ability to interfere with target binding.

To optimize neutralization assays:

• Determine the optimal antibody:target ratio through titration experiments

• Pre-incubate antibody and target protein before adding to the assay system

• Include appropriate controls to distinguish partial vs. complete neutralization

• Consider temperature and incubation time effects on neutralization efficiency

What are the binding kinetics of Y12 antibodies and how should they be interpreted?

Understanding the binding kinetics of Y12 antibodies provides crucial insights into their research utility. Surface plasmon resonance (SPR) studies with Anti-Bevacizumab Antibody (AY12) captured on CM5 chip via anti-mouse antibodies surface reveal that it binds human bevacizumab with an affinity constant of 0.08 nM . This extremely high affinity (sub-nanomolar range) indicates exceptional binding strength and stability of the antibody-antigen complex.

When interpreting binding kinetics data:

• Consider both association (kon) and dissociation (koff) rates, not just the equilibrium dissociation constant (KD)

• Compare affinities across different experimental conditions to ensure reproducibility

• Evaluate how binding kinetics translate to functional activity in your specific application

• Assess potential avidity effects if working with multivalent antigens

What purification methods are most effective for Y12 antibodies and how do they impact functional activity?

Y12 antibodies can be purified using several methods, with protein affinity chromatography being most common. The Anti-Bevacizumab Antibody (AY12) is purified using either Protein A or Protein G affinity purification , both of which provide >95% purity as determined by SDS-PAGE analysis. The choice between these methods should consider:

• Antibody isotype (Protein A has higher affinity for mouse IgG1 than Protein G)

• Required purity level for downstream applications

• Buffer compatibility with experimental systems

• Potential impact on antibody functional domains

Post-purification quality control is essential, with SDS-PAGE under reducing conditions being standard practice to verify purity. For the Anti-Bevacizumab Antibody (AY12), Coomassie Blue staining confirms purity greater than 95% , which is suitable for most research applications including binding and neutralization assays.

How should Y12 antibodies be reconstituted to maintain maximum activity?

Proper reconstitution of lyophilized Y12 antibodies is critical for maintaining their structural integrity and functional activity. For optimal performance with Anti-Bevacizumab Antibody (AY12), researchers should strictly follow the reconstitution protocol provided in the Certificate of Analysis . The typical reconstitution involves:

• Allowing the lyophilized product to equilibrate to room temperature

• Using appropriate sterile buffer (typically PBS or manufacturer-recommended buffer)

• Gentle mixing without vigorous shaking or vortexing

• Allowing sufficient time for complete dissolution

• Preparing aliquots for single use to avoid freeze-thaw cycles

After reconstitution, proper storage conditions must be maintained to preserve antibody activity. Any deviation from recommended reconstitution protocols may result in reduced binding capacity, aggregation, or compromised specificity.

What controls should be included when using Y12 antibodies in immunoprecipitation or immunodetection experiments?

When designing experiments with Y12 antibodies, appropriate controls are essential for reliable data interpretation. For immunoprecipitation studies with Anti-Sm [Y12] antibody, the following controls should be included:

• Isotype control: Use a non-specific mouse IgG3 kappa antibody to identify non-specific binding

• Input control: Analyze a portion of the pre-IP sample to confirm target presence

• Negative control: Process samples without antibody addition to detect non-specific pull-down

• Validation control: Include known positive samples where Sm protein complex presence is confirmed

For Anti-Bevacizumab Antibody (AY12) specificity validation, demonstrating selective binding to bevacizumab rather than other therapeutic antibodies is crucial . This specificity control ensures experimental results reflect true target interactions rather than artifact signals.

How can researchers troubleshoot non-specific binding issues with Y12 antibodies?

Non-specific binding can compromise experimental results when working with Y12 antibodies. Common troubleshooting approaches include:

• Optimize blocking conditions: Increase blocking agent concentration or try alternative blockers (BSA, non-fat milk, commercial blockers)

• Adjust antibody concentration: Titrate antibody concentration to find the optimal signal-to-noise ratio

• Modify wash stringency: Increase wash buffer ionic strength or add mild detergents

• Pre-clear samples: Remove components that may interact non-specifically with the antibody

• Validate specificity: Confirm antibody specificity through competitive binding assays

For the Anti-Bevacizumab Antibody (AY12), specificity testing demonstrates its selective recognition of bevacizumab . When non-specific binding occurs despite these measures, consider whether experimental conditions (buffer composition, pH, temperature) might be compromising antibody performance.

What factors influence Y12 antibody stability during experimental procedures?

Several factors can impact Y12 antibody stability and performance during research applications:

• Temperature fluctuations: Repeated freeze-thaw cycles significantly reduce antibody activity; aliquot upon reconstitution

• pH extremes: Maintain pH within physiological range (typically pH 6.5-8.0) for optimal performance

• Protein concentration: Both extremely low and high concentrations can promote aggregation or adsorption to surfaces

• Buffer composition: Certain buffer components may interfere with antibody-antigen interactions

• Mechanical stress: Excessive shaking, vortexing, or sonication can denature antibody structure

For Anti-Bevacizumab Antibody (AY12), storage in lyophilized state at -20°C or lower provides maximum stability . When working with reconstituted antibody, minimize exposure to adverse conditions that could compromise binding capacity or specificity.

How should researchers interpret binding affinity data from Y12 antibody experiments?

When analyzing binding affinity data for Y12 antibodies, consider multiple analytical perspectives:

• Affinity constant interpretation: The Anti-Bevacizumab Antibody (AY12) demonstrates an affinity constant of 0.08 nM for human bevacizumab , indicating extremely high binding strength. Affinity constants below 1 nM generally represent very strong interactions suitable for sensitive detection applications.

• Comparative analysis: Compare affinity values across different experimental conditions or antibody batches to ensure consistency.

• Functional correlation: Evaluate how binding affinity translates to functional activity in your specific application. High affinity doesn't always correlate with optimal functional performance.

• Detection limit considerations: Calculate theoretical detection limits based on affinity constants to determine the minimum detectable concentration of target antigens.

When reporting binding data, provide complete methodological details including immobilization strategy, measurement temperature, buffer composition, and analytical model used to calculate affinity constants.

How can Y12 antibodies contribute to autoimmune disease research beyond current applications?

Y12 antibodies offer significant potential for advancing autoimmune disease research. The Anti-Sm [Y12] antibody is currently used in quantitative radioimmunoassays for SLE patients, where antibodies to Sm are found in 20-30% of cases . Beyond this application, researchers can leverage Y12 antibodies to:

• Develop more sensitive diagnostic assays for earlier SLE detection

• Investigate the mechanistic relationship between snRNP complexes and autoimmune pathogenesis

• Create targeted immunotherapeutic approaches based on Sm epitope mapping

• Explore potential correlations between anti-Sm antibody titers and disease progression

The ability of Anti-Sm [Y12] to specifically recognize snRNP complexes makes it valuable for studying fundamental pre-mRNA splicing mechanisms, which are often dysregulated in autoimmune conditions . Future research could explore the therapeutic potential of modulating these pathways.

What methodological advances could improve Y12 antibody applications in structural biology?

Structural biology approaches using Y12 antibodies could benefit from several methodological improvements:

• Antibody engineering: Creating Fab fragments or single-chain variable fragments (scFvs) of Y12 antibodies to facilitate co-crystallization with target proteins

• Cryo-EM applications: Optimizing Y12 antibodies for use in cryo-electron microscopy to visualize large macromolecular complexes like snRNPs

• Hydrogen-deuterium exchange mass spectrometry: Using Y12 antibodies to stabilize specific conformations for detailed structural analysis

• Integrative structural biology: Combining multiple techniques (X-ray, NMR, computational modeling) with Y12 antibody binding data

For the Peptide Helix-Y12, structural studies have revealed its interaction with PPARs through a hydrogen bond network . This peptide forms a clamp inside the PPARs ligand-binding domain, reaching H3 and H12 helices . Similar detailed structural analyses of Y12 antibody-antigen complexes could provide insights for rational design of improved research tools.